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Abstract 
Background: Toxoplasma gondii is a zoonotic parasite of global importance. The outcome of infection in humans can 
depend on a number of factors including the infecting stage of the parasite, inoculating dose and virulence of the 
infecting strain. Molecular epidemiological studies have demonstrated an abundance of atypical strains of T. gondii 
in South America, many of which have been associated with more severe sequelae of infection. The aim of this study 
was to compare the virulence of T. gondii strains isolated in the Caribbean to a virulent Brazilian strain and an avirulent 
European strain.
Methods: One hundred and twenty Swiss CD‑1 mice were split into 8 groups of 15 mice and each group was 
inoculated with 200 tachyzoites of one of 8 isolates, comprising ToxoDB genotypes #1, #141, #265, #13, #3 and #6. Five 
mice per group were euthanized at day 8 post‑inoculation (p.i.) and parasite burden was determined in heart, lungs 
and eyes using quantitative PCR. Lungs and brain were also examined by histopathology and immunohistochemistry. 
The remaining 10 mice per group were part of a survival experiment to assess virulence. DNA was extracted from 
tachyzoites of each of the 8 T. gondii isolates and genotyped at four ROP gene loci, including ROP5, ROP16, ROP17 and 
ROP18 to look for association with markers of virulence.
Results: Infection with ToxoDB genotype #13 from the Caribbean resulted in 100% of mice being euthanized which 
was comparative to infection with the virulent Brazilian strain (ToxoDB genotype #6). Significantly higher parasite bur‑
dens were recorded in the lungs and eyes of mice infected with ToxoDB genotypes #13 and #6. Genotyping of ROP 
loci revealed that the virulent Caribbean isolates had a different ROP18/ROP5 allelic profile (3/1) to the virulent Brazil‑
ian isolate (1/3); however, the avirulent Caribbean isolate (ToxoDB genotype #1) had the same ROP18/ROP5 profile as 
the avirulent European isolate (ToxoDB #3) (both 2/2). Caribbean isolates of intermediate virulence (ToxoDB #141 and 
#265) all had the same ROP18/ROP5 allelic profile (2/2).
Conclusions: Isolates from the Caribbean with ToxoDB genotype #13 were acutely virulent for mice and comparable 
to a known virulent Brazilian isolate. The ROP protein allelic profile of the virulent Caribbean and Brazilian isolates dif‑
fered indicating that perhaps other factors are involved in predicting virulence. Understanding virulence is important 
for predicting disease outcome in humans and may also aid vaccine design as well as drug discovery.
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Background
Toxoplasma gondii is a ubiquitous intracellular parasite 
capable of infecting all warm-blooded animals, including 
humans [1]. Felids are the only definitive hosts shedding 
large numbers of oocysts into the environment in their 
faeces. Transmission routes of the parasite to humans 
include ingestion of infectious oocysts directly from the 
environment or in contaminated food or water, ingestion 
of tissue cysts in undercooked/raw infected meat, and 
vertical transmission from mother to foetus during a pri-
mary infection. Infection in immune competent people 
is usually mild or asymptomatic; however, immune com-
promised people and congenitally infected infants can 
suffer severe and life-threatening clinical signs, such as 
encephalitis, blindness or even death [2].
The population structure of T. gondii was originally 
thought to be clonal, consisting of three dominant line-
ages (designated Types I, II and III) [3]; however, it has 
become apparent that the parasite has much greater 
genetic variability and some genotypes are distributed in 
distinct geographical patterns [4]. In Europe and North 
America, clonal Types II and III dominate (as well as 
Type 12 in North America), whilst in South and Central 
America there is an abundance of atypical (non-clonal) 
strains with no clear genotypes dominating [4]. Virulence 
of T. gondii has been assessed in mice and varies depend-
ing on the infecting strain, with Type I genotypes caus-
ing 100% mortality irrespective of the inoculating dose 
and Types II and III causing intermediate or no mortality, 
depending on dose [5]. A recent study correlating viru-
lence markers with published virulence data for over 200 
isolates from all over the world noted that isolates from 
North America, Europe, North Africa and Asia were 
non-lethal to mice at low infectious doses whereas a large 
proportion of isolates from South America were lethal to 
mice [6].
Polymorphic rhoptry proteins (ROP) are secreted by 
the parasite upon invasion and have been shown to be 
involved in host-parasite interactions and immune eva-
sion [7]. Recently, ROP5 and ROP18 alleles were identi-
fied as key determinants of virulence in mice [6]. Studies 
on the population genetics and epidemiology of T. gondii 
have suggested a link between the geographical distribu-
tion of isolates and more severe clinical signs in immune 
competent humans. In South America (specifically, 
French Guiana and Suriname), there have been reports 
of severe systemic toxoplasmosis resulting in death of 
immune competent people infected with an atypical 
strain of the parasite [8]. Similarly, the prevalence, sever-
ity and risk of ocular toxoplasmosis is much greater in 
Brazil than in North America and Europe [9].
The virulence of T. gondii strains in outbred mice 
appears to correlate with disease manifestations in 
humans making the mouse a useful tool for assessing 
virulence and predicting possible outcomes of human 
infection [10, 11]. The aim of this study was to determine 
the virulence of previously identified atypical strains of T. 
gondii isolated in the Caribbean [12] and compare them 
with a known virulent Brazilian strain [13] and an aviru-
lent European strain [14].
Methods
In vitro culture of tachyzoites
Toxoplasma gondii tachyzoites of the strains listed in 
Table  1 were grown in pre-cultured Vero cells (ATCC® 
CCL-81™) in IMDM (supplemented with 2% FCS, 200 
IU/ml penicillin and 200 μg/ml streptomycin) at a ratio 
of one Vero cell to two T. gondii tachyzoites. On the day 
of inoculation, tachyzoites were enumerated using a 
haemocytometer and one extra vial per group (Table  1) 
was prepared and stored at -20  °C for DNA extraction 
and confirmation of genotype by PCR-RFLP.
Mouse virulence study
One hundred and twenty female outbred Swiss CD-1 
mice were housed in groups of five with access to 
food and water ad libitum. The mice were split into 
8 groups of 15 mice. Within each group, 5 mice were 
euthanised on day 8 post-inoculation (p.i.) to allow for 
comparison of parasite burden and distribution at one 
time-point, and 10 mice were part of a survival experi-
ment to assess virulence of the isolates. All mice were 
inoculated, intraperitoneally, with 200 tachyzoites 
(Table 1). Although only a single dose was chosen; this 
was based on previous experiments demonstrating that 
virulent isolates resulted in 100% mortality irrespective 
of dose [15–18] and that avirulent and intermediately 
virulent isolates may also be identified at a lower dose 
[19, 20]. Mice were monitored and scored twice daily 
(at least) for signs of clinical toxoplasmosis. Any mice 
that reached a maximum permissible score for 2 con-
secutive days and were deemed unlikely to recover were 
humanely euthanised in accordance with the Animals 
(Scientific Procedures) Act 1986. Remaining mice were 
euthanised when they reached the end of the experi-
ment (day 8 p.i. or day 28 p.i.). Immediately following 
euthanasia, mice were bled by cardiac puncture and 
sera isolated as previously described [12]. One cer-
ebral hemisphere, one lung and both eyes from each 
mouse were transferred to clean 2 ml tubes and stored 
at -80 °C for DNA extraction, while one cerebral hemi-
sphere and one lung were stored in 10% buffered forma-
lin for histopathology examination (described below). 
All sera from mice in the survival experiment (10 per 
group) were tested for antibodies to T. gondii using an 
indirect ELISA (ID Screen® Toxoplasmosis Indirect 
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Multi-species, IDvet, Montpellier, France) according to 
the manufacturer’s instructions. Sera from the 5 mice 
per group which were euthanised at day 8 p.i. were 
not tested as the ELISA detects IgG and these samples 
would have been negative (too early in infection).
DNA extraction and quantitative PCR
One cerebral hemisphere from each mouse was homog-
enised in 1 ml PBS using a syringe and 18G needle fol-
lowed by a 21G needle. One lung from each mouse was 
homogenised in 1 ml Nuclei Lysis Solution (Promega 
Corporation, Southampton, UK) in Precellys tubes con-
taining CK28 ceramic beads. Both eyes from each mouse 
were homogenised, together, in 1 ml Nuclei Lysis Solu-
tion using an 18G needle. DNA was extracted from 
400 μl of each homogenised tissue using the Wizard® 
genomic DNA purification protocol (Promega Corpora-
tion, Southampton, UK) [21]. The final pellet of DNA was 
resuspended in 200 μl nuclease-free water and stored at 
-20 °C until required for PCR.
Quantitative PCR, targeting the 529 bp repeat ele-
ment, was carried out in triplicate according to a previ-
ously described method [22] with slight modifications. 
The 20 μl reaction mixture consisted of 10 μl 2× Light-
cycler® 480 Probes Master mix (Roche), 0.7 μM of each 
primer (Tox-9Fand Tox-11R), 0.1 μM of Tox-TP1, 0.2 μM 
of CIAC-probe, 0.02 fg of CIAC and 250 ng of template 
DNA in 8 μl. Sequences for primers and probes, as well 
as PCR conditions have been described previously [12, 
22].
Genetic characterisation of T. gondii by PCR‑RFLP
DNA was extracted from aliquots of mouse inocula 
(tachyzoites representing each isolate) using protein-
ase K (Promega). Briefly, 100 μg/ml proteinase K was 
added to each sample prior to incubation at 50 °C for 90 
min, followed by 95 °C for 15 min. Samples were cen-
trifuged at 13,000× g for 5 min at 4 °C and the super-
natant (containing the DNA) was transferred to a clean 
2 ml tube and stored at -20 °C until required. The Tox-
oDB genotype of each isolate was confirmed using a 
multiplex nested PCR-RFLP targeting 10 genetic mark-
ers, including SAG1, SAG2 (5′- and 3′-SAG2 and Alt.
SAG2), SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1 
and Apico as previously described [23, 24]. Genotypes 
were determined using RFLP banding profiles of ref-
erence strains RH (Type I), M4 (Type II variant; used 
for all markers except Apico where Type II strain Me49 
was used instead) and NED (Type III) [25].
Genotyping of loci known to be associated with viru-
lence (ROP5, ROP16 and ROP18) was carried out using 
PCR-RFLP methods as previously described [6, 24]. For 
ROP18, two sets of primers were used: one to amplify 
a repetitive sequence (DEL) in the promoter region of 
archetypal Type I and II alleles; and one to amplify the 
upstream promoter insertion sequence (UPS) of the 
archetypal Type III allele [6]. As the UPS fragment is 
only amplified for Type III alleles no restriction digest 
was required. A double digest was performed on the 
DEL fragment and banding patterns were compared to 
reference strains RH and M4 [6].
Table 1 Isolates and groupings for experimental infection with 200 T. gondii tachyzoites of different genotypes
Group no. Inoculating isolate Origin of isolate ToxoDB RFLP genotype # No. of mice Day p.i. of intended 
euthanasia
Reference
1 TgCkStk12 St. Kitts 1 (type II) 5 8 [12]
10 28
2 TgCkStK13 141 (atypical) 5 8
10 28
3 TgCkStK10 141 (atypical) 5 8
10 28
4 TgCkStK2 265 (atypical) 5 8
10 28
5 TgCkStK9 13 (atypical) 5 8
10 28
6 TgCkStK11 13 (atypical) 5 8
10 28
7 Moredun M4 UK 3 (type II variant) 5 8 [15]
10 28
8 TgCatBr71 Brazil 6 (atypical) 5 8 [13]
10 28
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Histopathology and immunohistochemistry
Formalin-fixed samples of brain and lung were processed 
routinely and embedded in paraffin wax. A formalin fixed 
paraffin-wax embedded liver from a mouse known to 
be infected with T. gondii was used as a positive control. 
Sections were cut at 5 µm and stained with haematoxylin 
and eosin (HE) for histological examination. For immu-
nohistochemistry (IHC), serial sections were cut at 5 µm 
and placed on treated glass slides (Superfrost Plus, Men-
zel-Glaser, Braunschweig, Germany). For IHC, tissues 
were deparaffinised and hydrated before endogenous 
peroxidase was blocked with 3% hydrogen peroxide and 
methanol solution for 20 min at room temperature. For 
heat-induced epitope retrieval (HIER), slides were placed 
into citrate buffer (0.01M citric acid, pH6) and then auto-
claved for ten minutes at 121 °C. Normal goat serum 
(25%) was applied to all slides for at least 30 min at room 
temperature. Toxoplasma gondii rabbit polyclonal anti-
body (Thermo-Fisher Scientific, Illinois, USA), diluted 
1:600, was applied to all samples overnight at 4 °C. For 
the negative control, normal rabbit serum (HKV1) was 
used at 1:500. After 18–24 hours, goat anti-rabbit HRP-
labelled polymer (DAKO EnVision+, Carpinteria, Cali-
fornia, USA) was applied to the slides for 30 min at room 
temperature. AEC (3-amino-9-ethylcarbazole) chromo-
gen solution (Vector Laboratories, Peterborough, UK) 
was made as instructed in the manufacturers guide-
lines and applied to slides for 30 min at room tempera-
ture. All tissues were counterstained with hematoxylin, 
then mounted with Marienfeld microscope cover slips 
(Lauda-Königshofen, Germany) using Shandon Consul-
Mount™ Histology Formulation (Xylene based). Sec-
tions of organ samples collected from the eight groups 
of mice were assessed microscopically and the severity of 
pathology was based on the number and size of lesions 
observed. The presence of T. gondii was assessed by 
immunohistochemistry.
Statistical analysis
The virulence of the isolates was assessed by estimating 
survival curves using the Kaplan-Meier method based on 
10 mice per group. The overall difference between sur-
vival curves was tested for statistical significance using 
the asymptotic log-rank test for multiple groups [26] 
based on a chi-square probability distribution with 7 
degrees of freedom. This was followed by post-hoc pair-
wise comparisons between curves using 2-group log-
rank tests, with the resulting P-values being corrected for 
multiple comparisons using the Benjamini-Hochberg’s 
procedure [27] to control for false discovery rate (FDR).
Parasite burden in lung, brain and eyes was measured 
using a quantitative PCR and the data were analysed 
using a linear mixed model (LMM) fitted by restricted 
maximum likelihood (REML) to log-transformed data, 
with “Group” and “Organ”, and the interaction between 
them, as fixed effects and “Animal” as a random effect. 
Post-hoc pairwise comparisons between organs and 
groups were conducted from the LMM estimates, with 
the corresponding P-values being adjusted for FDR.
Statistical test significance was assessed at the usual 5% 
significance level. The statistical analyses were conducted 
on the R system for statistical computing v3.4 [28].
Results
Mouse survival experiment
During the 28-day survival experiment, only 45% (36/80) 
of mice survived until the end of the experiment (Fig. 1). 
Forty-four mice (55%) had to be euthanised due to signs 
of clinical toxoplasmosis. Of the 44 mice euthanised, 20 
had been infected with ToxoDB genotype #13 (St. Kitts 
isolates TgCkStK9 and TgCkStK11; Groups 5 and 6, 
respectively), 10 with ToxoDB genotype #6 (Brazilian 
BrI isolate TgCatBr71; Group 8), 9 with ToxoDB geno-
type #141 (5 with St. Kitts isolate TgCkStK13 and 4 mice 
with St. Kitts isolate TgCkStK10; Groups 2 and 3, respec-
tively), 3 with ToxoDB genotype #265 (St. Kitts isolate 
TgCkStK2; Group 4) and 2 with ToxoDB genotype #1 
(M4; Group 7). Kaplan-Meier survival curves were plot-
ted to present the survival rate of mice for each group 
(Fig. 1). A log-rank test demonstrated an overall statisti-
cally significant difference in survival between all groups 
of mice (χ2 = 54.07, df = 7, P < 0.001). Pairwise compari-
sons revealed that mice infected with ToxoDB genotype 
#13 (Groups 5 and 6) and ToxoDB genotype #6 (Group 
8) had a significantly lower survival rate in comparison to 
all other groups (P < 0.001). Mice infected with ToxoDB 
genotype #1 (Group 1) had a statistically significantly 
higher survival rate compared to all other groups of mice 
(P < 0.05) except Group 7 (European M4 isolate; ToxoDB 
genotype #3) and Group 4 (ToxoDB genotype #265) (P = 
0.019 and P = 0.094, respectively).
Distribution and burden of parasites
Parasite distribution and burden were investigated in 
five mice from each group euthanised at day 8 post-
infection. Using the 529-bp qPCR, T. gondii DNA was 
detected in the lungs of 100% (40/40) of mice, in the 
brain tissue of 77.5% (31/40) of mice and in the eyes 
of 80% (32/40) of mice. At day 8 p.i., there was a sta-
tistically significantly higher mean parasite burden in 
the lungs compared to brain and eyes (F(2,63) = 126.71, 
P < 0.001; Fig.  2). The highest burden in the lungs 
(Fig.  2a) was evident in mice in Group 8 inoculated 
with the Brazilian BrI isolate (average T. gondii DNA 
concentration of 173.6 pg) followed by mice in Group 
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5 inoculated with the St. Kitts ToxoDB genotype #13 
(average T. gondii DNA concentration of 93.1 pg). Mice 
in Group 1, inoculated with the Type II St. Kitts isolate 
TgCkStK12 (ToxoDB genotype #1), demonstrated the 
lowest lung burden with an average T. gondii DNA con-
centration of only 0.4 pg. Similar to the lung, the high-
est parasite burden in the brain (Fig. 2b) was observed 
in mice in Group 8 (average T. gondii DNA concentra-
tion of 7.7 pg), followed by Group 2 (average T. gondii 
DNA concentration of 4.2 pg) and then Group 5 (aver-
age T. gondii DNA concentration of 3.5 pg). The para-
site burden in the eyes (Fig.  2c) was low compared to 
lung and brain. Again, the highest burden was observed 
in mice in Group 8 (11.3 pg), followed by Group 5 (1.5 
pg) and then Group 7 (1.2 pg). When comparing para-
site burden as a whole, the overall levels were generally 
higher in Groups 5 and 8, representing mice infected 
with ToxoDB genotype #13 (St. Kitts isolate TgCkStK9) 
and ToxoDB genotype #6 (Brazilian isolate TgCatBr71), 
respectively. For Group 8, the overall parasite bur-
den was statistically significantly higher that all other 
groups (P < 0.001), except for Group 5 (t(32) = -1.48, P 
= 0.173) and marginally Groups 2 and 7 (t(32) = -2.28, P 
= 0.054; t(32) = 2.22, P = 0.055). The pattern of differ-
ences in mean parasite burden between groups did not 
change statistically significantly across organs (F(14,63) = 
1.55, P = 0.120).
Genetic characterisation and markers for virulence
Analysis of each of the 8 isolates by PCR-RFLP target-
ing 10 genetic markers (SAG1, SAG2 (5’, 3’ and Alt.), 
SAG3, BTUB, GRA6, c29-2, c22-8, L358, PK1 and 
Apico) revealed their expected genotypes [12] confirm-
ing that they had not changed during in vitro culture of 
tachyzoites for inoculation (data not shown). Results of 
PCR-RFLP analysis of polymorphic loci ROP5, ROP16, 
ROP17 and ROP18 are given in Table  2. For ROP5 and 
ROP18, three different alleles were identified, with allele 
3 predominating for both loci, particularly ROP18. Loci 
ROP16 and ROP17 were less polymorphic with just two 
alleles being identified, although allele 1 predominated 
for both. Both the virulent isolates from St. Kitts (Tox-
oDB genotype #13; Groups 5 and 6) displayed a differ-
ent profile to the virulent isolate from Brazil (ToxoDB 
genotype #6; Group 8). Of the 3 isolates of intermediate 
virulence, two isolates (St. Kitts isolates TgCkStK13 and 
TgCkStK10) displayed the same allelic profile (alleles 3, 3, 
1, 1 for ROP5, ROP18, ROP16 and ROP17, respectively) 
and the other (St. Kitts isolate TgCkStK2) differed at the 
ROP17 locus (allele 2 rather than allele 1).
Fig. 1 Kaplan‑Meier surival curves for each group of mice infected with one of 8 isolates of T. gondii (n = 10 per group). All mice (100%) in Group 1 
surived until the end of the experiment (day 28 p.i.), whereas no mice (0%) survived in Groups 5, 6 and 8. Mice in Groups 2, 3, 4 and 7 had survival 
rates of 50%, 60%, 70% and 80%, respectively
Page 6 of 10Hamilton et al. Parasites Vectors          (2019) 12:104 
Serology
All mice in the survival experiment which were euthan-
ised later than day 16 p.i. (44/80) had detectable anti-
T. gondii IgG antibodies in their sera (data not shown). 
Mice in the survival experiment which were euthanised 
earlier than this time point were negative by ELISA 
(data not shown).
Histopathology
Lung and brain tissue from five mice from each group 
euthanised at day 8 p.i. were examined. Inflammatory 
infiltrate and necrotic foci were present in the lungs of all 
mice examined but these were more severe in the mice 
in Group 5 (St. Kitts isolate TgCkStK9, ToxoDB geno-
type #13). Mice from Groups 5, 6 and 8 all showed large 
Fig. 2 Parasite burden in mouse tissues. Mean quantity (± SE) of T. gondii DNA, as detected by the 529 bp repeat element qPCR, in the lungs (a), 
brain (b) and eyes (c) of mice euthanized at day 8 p.i. (n = 5 per group)
Table 2 Genotyping of isolates with polymorphic loci ROP5, ROP18, ROP16 and ROP17
Group Isolate ToxoDB 
genotype #
ROP5 ROP18 ROP16 ROP17 Virulence % mortality
1 TgCkStk12 1 2 2 2 2 Avirulent 0
2 TgCkStK13 141 3 3 1 1 Intermediate 50
3 TgCkStK10 141 3 3 1 1 Intermediate 40
4 TgCkStK2 265 3 3 1 2 Intermediate 30
5 TgCkStK9 13 1 3 1 1 Virulent 100
6 TgCkStK11 13 1 3 1 1 Virulent 100
7 Moredun M4 3 2 2 2 2 Avirulent 20
8 TgCatBr71 6 3 1 1 1 Virulent 100
Page 7 of 10Hamilton et al. Parasites Vectors          (2019) 12:104 
numbers of parasite in the lungs. Although the lungs 
from mice in Group 8 displayed the highest burden of 
parasites, the pathology observed was not as severe as 
in Group 5. Very low numbers of parasites and mild/no 
pathology were seen in the brains of infected mice, which 
likely reflects the early time point of sample collection 
(day 8 p.i.).
Discussion
In the present study, two isolates from St. Kitts, which 
were both ToxoDB genotype #13, proved to be highly 
virulent for mice and showed a level of pathogenicity 
similar to that of the known virulent Brazilian isolate 
BrI (ToxoDB genotype #6). All mice infected with these 
isolates (Groups 5, 6 and 8) showed severe signs of clini-
cal toxoplasmosis, with maximum permissible scores for 
2 consecutive days, and 100% were euthanised by days 
12, 14 and 16, respectively for Groups 5, 8 and 6. Mice 
in Groups 5 and 8 also had higher parasite burdens in 
their lungs compared to other mice and mice in Group 
5 had higher inflammatory infiltrate and necrotic foci 
in comparison to mice from the other groups. We have 
previously reported the potential virulence of ToxoDB 
genotype #13 in a bioassay where mice were inoculated 
with T. gondii-infected chicken tissues and 8 out 9 mice 
which received this genotype had to be euthanised due 
to clinical toxoplasmosis [12]. It is noteworthy that the 
findings in the present study are in contrast to previous 
studies involving ToxoDB genotype #13 which have all 
described the isolate as avirulent for mice [20, 29–35]. 
In six of the eight studies, virulence of the isolates was 
determined following a bioassay where tissues from 
dogs [30], chickens [31, 33], cats [32], goats [20, 35] and 
a howler monkey [34] were homogenised and inoculated 
into mice with no prior determination of parasite burden 
in the tissues. Therefore, it is possible that the inoculat-
ing dose may have been lower than that used in the pre-
sent study and resulted in a less severe infection. In the 
present study, two different isolates of genotype #13 were 
used and both resulted in 100% mortality confirming the 
virulence of this isolate in this study. Toxoplasma gondii 
isolates of the same ToxoDB genotype but different lev-
els of virulence have been described previously. Rego 
et al. [20] described two isolates (TgPgBrPI 8 and TgPg-
BrPI 1), both designated ToxoDB genotype #163, which 
resulted in 100% mortality and 0% mortality, respectively, 
in mice infected with 1, 10, 100 or 1000 tachyzoites. Also, 
isolates with the same ToxoDB genotype (#7) have been 
described as 100% virulent in one study [20] and of inter-
mediate virulence in another [36] despite both studies 
using a titrated dose of tachyzoites.
ToxoDB genotype #13 has been isolated from a patient 
from the Caribbean with toxoplasmic lymphadenopathy 
and a history of toxoplasmic encephalitis [37] and phy-
logenetic analysis revealed that the strain clustered more 
closely with Type I strains than other strains [38]. This 
isolate (PSP-2003-ERO) had originally been genotyped 
using microsatellite markers and was defined as “Carib-
bean 1” genotype [39]. Caribbean 1 genotype (genotyped 
using microsatellite markers) has also been isolated at 
post mortem from an AIDS patient with toxoplasmic 
encephalitis and a transplant patient who died from pul-
monary toxoplasmosis [39] and although these isolates 
remain to be genotyped using the panel of PCR-RFLP 
markers, it is highly likely that they are also ToxoDB gen-
otype #13 [12]. This further highlights the potential viru-
lence of this genotype. Indeed, it has been demonstrated 
that T. gondii isolates containing many Type I alleles are 
more pathogenic and likely to cause more severe disease 
[11, 40]. ToxoDB genotype #13 has Type I alleles at 5 out 
of 10 of the PCR-RFLP markers used to define it. It is also 
amongst the top ten most frequently isolated genotypes 
in South America [4].
Of note in the present study, was the burden of T. gon-
dii in the eyes of mice infected with the Brazilian BrI iso-
late (Group 8). These mice had a statistically significantly 
higher burden in comparison to most of the other groups. 
BrI (ToxoDB genotype #6) is the second most frequently 
occurring isolate in Central and South America [4], and 
severe ocular toxoplasmosis has been shown to be diag-
nosed more often in this part of the world. For exam-
ple, ocular involvement in T. gondii-infected patients in 
Europe and the USA has been estimated at 2% in com-
parison to almost 18% in Brazil [11, 41, 42]. Furthermore, 
congenitally infected children in Brazil are five times 
more likely to develop ocular lesions than European chil-
dren, and the lesions are more severe and likely to lead to 
visual impairment [43].
ToxoDB genotype #141 proved to be of intermediate 
virulence in the present study, resulting in 50% and 40% 
mortality of mice in Groups 2 and 3, respectively. This 
genotype was previously isolated from a fox in the USA 
and was shown to be acutely virulent for mice even at low 
doses [18]. In contrast, in another study, this genotype 
was isolated from cats in St. Kitts (Caribbean) and was 
shown to be avirulent for mice [32]. In the latter study, 
the determination of virulence was based on a bioassay 
involving the inoculation of mice with digested tissues 
from seropositive cats and not a controlled study with a 
defined dose of parasites (as in the former study). This 
could explain the discrepancy between the results and 
highlights the potential pitfalls in assigning virulence 
based on bioassays in which the dose is not controlled, 
as outlined above for ToxoDB genotype #13. Differences 
in virulence may also be a reflection of the methods used 
to assign genotypes. Whilst PCR-RFLP is a widely used 
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method, it is based on restriction enzymes detecting sin-
gle nucleotide polymorphisms at a limited number of loci 
so it is possible that isolates which appear to have the 
same ToxoDB genotype may display undetected poly-
morphisms at other loci. Perhaps multi-locus sequence 
typing of virulence markers would offer a more robust 
approach, although this is more costly and time-consum-
ing [11].
Rhoptry proteins (ROP) have been shown to play an 
important role in host-parasite interactions. They are 
secreted by the rhoptry bulb of T. gondii upon invasion 
of the host cell and act at the parasitophorous vacuole to 
inhibit the localisation of immunity-regulated GTPases 
(IRGs) and guanylate-binding proteins (GBPs), both of 
which have been shown to be host resistance factors to 
pathogens [44, 45]. Genetic crosses between the arche-
typal lineages of T. gondii and the subsequent analysis of 
their progeny resulted in the identification of ROP18 and 
ROP5 as key determinants of virulence in mice [46, 47]. 
Two other proteins, ROP16 and ROP17, have also been 
shown to play a role in the modulation of host responses 
to T. gondii invasion and the avoidance of parasite clear-
ance [48, 49]. In a recent study, 240 T. gondii strains from 
South America and Asia were analysed using PCR-RFLP 
targeting ROP18, ROP5, ROP16 and ROP17 and the 
authors concluded that allele 1 of ROP18 in combina-
tion with allele 3 of ROP5 were key determinants of viru-
lence in mice [6]. In the present study, ToxoDB genotype 
#13 (Groups 5 and 6) and ToxoDB genotype #6 (Group 
8) were both associated with 100% mortality in mice; 
therefore, it was expected that they would have the vir-
ulent ROP profile. However, only ToxoDB genotype #6 
had allele 1 of ROP18 and allele 3 of ROP5, whereas Tox-
oDB genotype #13 had allele 3 of ROP18 and allele 1 of 
ROP5. It may be the case that other genetic factors are 
involved in virulence or that although the virulent geno-
type profile applies to most virulent strains, it does not 
apply to all. For example, amongst the strains analysed by 
Shwab et al. [6], one was associated with 75% mortality in 
mice and had the same ROP18 and ROP5 alleles as Tox-
oDB genotype #13 in this study. Similarly, 39 out of 106 
strains, accounting for 37% of those classified as lethal for 
mice, had allele 4 of ROP18 and allele 3 of ROP5. Also, 
out of 134 non-virulent isolates, only 9 had the ROP18/5 
allelic combination of 3/1. Whole genome sequencing 
of virulent and avirulent genotype #13 isolates may help 
identify differences between the isolates and potentially 
other markers for virulence.
The isolates of intermediate virulence in this study had 
the same ROP profile except for one isolate which dif-
fered at the ROP17 locus. It is of note that this isolate 
(ToxoDB genotype #265), which had the same ROP17 
allele as the avirulent isolates (ToxoDB genotypes #1 
and #3), was associated with 30% mortality which is the 
threshold for designating an isolate as being of interme-
diate virulence (≥ 30% mortality) or avirulent (< 30% 
mortality). Perhaps there is a role for ROP17 in deter-
mining virulence, although this has not been described 
before. The ROP18/ROP5 allelic profile of 3/3 displayed 
by the isolates of intermediate virulence in this study is in 
accordance with previous studies where this allelic pro-
file has been described for isolates causing varying levels 
of mortality [6]. The avirulent isolates had the same ROP 
profile with allele 2 at all loci, which is expected in Type 
II/Type II variant strains and has been described before 
[6].
Whilst it appears that ROP proteins play a role in 
determining virulence, it is likely to also involve a num-
ber of other parasite and host genetic factors. The major-
ity of investigative studies into the mechanisms behind 
the conferrence of virulence by ROP proteins have been 
focused on mice but recent studies have shown that nei-
ther ROP18 nor ROP5 affected the survival of T. gondii 
in human cells [50]. In mice, ROP18 has been shown to 
phosphorylate and inactivate IFN-γ-induced IRGs thus 
preventing disruption of the parasitophorous vacuole 
and killing of the parasite; however, humans only have 
two IRG genes so it is unlikely that the same mechanism 
confers virulence in the human host [50].
Conclusions
The results of this study have demonstrated that the Tox-
oDB genotype #13 isolates from the Caribbean displayed 
the same level of virulence as the ToxoDB genotype #6 
from Brazil, resulting in 100% mortality of mice. The 
ToxoDB genotype #1 isolate from the Caribbean was 
similar to the avirulent European isolate (ToxoDB geno-
type #3). Whilst the isolates used in this study originated 
from animals, they represent the strains circulating in 
the environments of the Caribbean, Europe and South 
America which may cause disease in humans. Given the 
more severe sequelae associated with atypical strains 
it is imperative to understand their level of virulence so 
that disease outcome may potentially be predicted. This 
becomes even more important with the knowledge that it 
is possible for previously infected humans (and animals) 
to become re-infected with an atypical strain [17, 51]. 
A greater understanding of parasite virulence not only 
allows for the potential to predict disease outcome, it may 
also aid vaccine design, a more specific treatment regime 
as well as the development of new drug compounds [52]. 
Saraf et al. [10] recently called for a standardized meth-
odology for determining T. gondii virulence in mice to 
allow for direct comparison between studies. Whilst this 
is much needed, it must also be recognised that ethical 
guidelines for working with laboratory animals differ 
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between regions (particularly Europe and the Americas) 
and have to be taken into consideration when conducting 
experiments.
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